amifostine anhydrous has been researched along with Disease Models, Animal in 33 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of amifostine, N-acetyl cysteine (NAC), and leuprolide as a scavenger in a rat endometriosis model." | 7.80 | Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: a randomized controlled trial. ( Dagdeviren, A; Gulumser, C; Mulayim, B; Onalan, G; Zeyneloglu, H, 2014) |
| "To assess the effects of amifostine, N-acetyl cysteine (NAC), and leuprolide as a scavenger in a rat endometriosis model." | 3.80 | Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: a randomized controlled trial. ( Dagdeviren, A; Gulumser, C; Mulayim, B; Onalan, G; Zeyneloglu, H, 2014) |
| "A phase separation inhibitor, WR77913 [S-3(amino-2-hydroxypropyl) phosphorothioate], was tested for its effects on lens opacification in the radiation (RAD), selenite (SEL), galactose (GAL), streptozotocin (STZ), and Royal College of Surgeons (RCS) models for cataract." | 3.68 | Phase separation inhibitors and lens transparency. ( Clark, JI; Livesey, JC; Steele, JE, 1993) |
| "A mouse model of pulmonary fibrosis was established using BLM." | 1.91 | Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway. ( Cheng, Y; Du, J; Huang, S; Pan, L; Wu, X; Yang, W; Zhang, M; Zhang, Y; Zhu, H, 2023) |
| "Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively." | 1.51 | Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. ( Benel, L; Bloy, C; Bricout, D; Chargari, C; Clémenson, C; Deutsch, E; Haddad, R; Liu, W; Mondini, M; Soyez-Herkert, L; Wang-Zhang, X, 2019) |
| " Despite this, none of the adverse effects of 0." | 1.35 | In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. ( Baverel, G; Dubourg, L; Michoudet, C; Yaseen, Z, 2008) |
| "Glycerol-induced acute renal failure is an experimental model for myoglobinuric nephropathy." | 1.33 | Effects of amifostine on glycerol-pretreated rabbit kidneys. ( Bali, M; Barun, S; Dileköz, E; Ercan, ZS; Erten, Y; Ertoy, D; Müftüoglu, S; Sarioglu, Y; Sucak, G; Tekeli, N, 2005) |
| "The WR-1065 tumor portal dosing AUC15-60 was 40% of systemic dosing, and tumor concentrations following portal dosing were one-fifth of that following systemic dosing." | 1.32 | Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. ( DeRemer, SJ; Dou, C; Ensminger, WD; Levi, M; Smith, DE, 2004) |
| "Chemoprotective agents reduce the toxic side effects of chemotherapy agents such as cisplatin." | 1.32 | WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. ( Blakley, BW; Burgio, DL; Church, MW; Gupta, AK, 2004) |
| "For a model of advanced ovarian cancer, mice received tumor cell injections on day 0 and did not begin drug treatment until tumors were palpable (0." | 1.29 | Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. ( Capizzi, RL; Johnson, CS; Lopez, MH; Paine, GD; Taylor, CW, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yang, W | 1 |
| Pan, L | 1 |
| Cheng, Y | 1 |
| Wu, X | 1 |
| Huang, S | 1 |
| Du, J | 1 |
| Zhu, H | 1 |
| Zhang, M | 1 |
| Zhang, Y | 1 |
| Zhang, J | 1 |
| Li, K | 1 |
| Zhang, Q | 1 |
| Zhu, Z | 1 |
| Huang, G | 1 |
| Tian, H | 1 |
| Wu, SZ | 1 |
| Tao, LY | 1 |
| Wang, JN | 1 |
| Xu, ZQ | 1 |
| Wang, J | 1 |
| Xue, YJ | 1 |
| Huang, KY | 1 |
| Lin, JF | 1 |
| Li, L | 1 |
| Ji, KT | 1 |
| Barbosa, SCM | 1 |
| Pereira, VBM | 1 |
| Wong, DVT | 1 |
| Santana, APM | 1 |
| Lucetti, LT | 1 |
| Carvalho, LL | 1 |
| Barbosa, CRN | 1 |
| Callado, RB | 1 |
| Silva, CAA | 1 |
| Lopes, CDH | 1 |
| Brito, GAC | 1 |
| Alencar, NMN | 1 |
| Lima-Júnior, RCP | 1 |
| Clémenson, C | 1 |
| Liu, W | 1 |
| Bricout, D | 1 |
| Soyez-Herkert, L | 1 |
| Chargari, C | 1 |
| Mondini, M | 1 |
| Haddad, R | 1 |
| Wang-Zhang, X | 1 |
| Benel, L | 1 |
| Bloy, C | 1 |
| Deutsch, E | 1 |
| Kajbafzadeh, AM | 1 |
| Sabetkish, N | 1 |
| Sabetkish, S | 1 |
| Javan-Farazmand, N | 1 |
| Harsini, S | 1 |
| Tavangar, SM | 1 |
| Onalan, G | 1 |
| Gulumser, C | 1 |
| Mulayim, B | 1 |
| Dagdeviren, A | 1 |
| Zeyneloglu, H | 1 |
| Sarhaddi, D | 1 |
| Tchanque-Fossuo, CN | 1 |
| Poushanchi, B | 1 |
| Donneys, A | 2 |
| Deshpande, SS | 2 |
| Weiss, DM | 1 |
| Buchman, SR | 2 |
| Akbulut, S | 1 |
| Elbe, H | 1 |
| Eris, C | 1 |
| Dogan, Z | 1 |
| Toprak, G | 1 |
| Otan, E | 1 |
| Erdemli, E | 1 |
| Turkoz, Y | 1 |
| Cengiz, K | 1 |
| Goksu, E | 1 |
| Cengiz, A | 1 |
| Ozsoy, O | 1 |
| Tan, R | 1 |
| Demir, N | 1 |
| Gurer, I | 1 |
| Kazan, S | 1 |
| Chen, CH | 1 |
| Kuo, ML | 1 |
| Wang, JL | 1 |
| Liao, WC | 1 |
| Chang, LC | 1 |
| Chan, LP | 1 |
| Lin, J | 1 |
| Polyatskaya, Y | 1 |
| Nelson, NS | 1 |
| Rodriguez, JJ | 1 |
| Zheutlin, AR | 1 |
| Felice, PA | 1 |
| Bougioukas, I | 1 |
| Didilis, V | 1 |
| Emigholz, J | 1 |
| Waldmann-Beushausen, R | 1 |
| Stojanovic, T | 1 |
| Mühlfeld, C | 1 |
| Schoendube, FA | 1 |
| Danner, BC | 1 |
| Wong, AK | 1 |
| Mei, L | 1 |
| Soares, MA | 1 |
| Schönmeyr, BH | 1 |
| Mehrara, BJ | 1 |
| Damron, TA | 3 |
| Margulies, BS | 2 |
| Strauss, JA | 2 |
| O'Hara, K | 1 |
| Spadaro, JA | 3 |
| Farnum, CE | 2 |
| Margulies, B | 1 |
| Morgan, H | 1 |
| Allen, M | 1 |
| Strauss, J | 1 |
| Spadaro, J | 1 |
| Damron, T | 1 |
| Levi, M | 1 |
| DeRemer, SJ | 1 |
| Dou, C | 1 |
| Ensminger, WD | 1 |
| Smith, DE | 1 |
| Church, MW | 1 |
| Blakley, BW | 1 |
| Burgio, DL | 1 |
| Gupta, AK | 1 |
| Barun, S | 1 |
| Ertoy, D | 1 |
| Dileköz, E | 1 |
| Müftüoglu, S | 1 |
| Erten, Y | 1 |
| Sucak, G | 1 |
| Bali, M | 1 |
| Tekeli, N | 1 |
| Sarioglu, Y | 1 |
| Ercan, ZS | 1 |
| Horton, JA | 1 |
| Luther, J | 1 |
| Yaseen, Z | 1 |
| Michoudet, C | 1 |
| Baverel, G | 1 |
| Dubourg, L | 1 |
| Thompson, JS | 1 |
| Asmis, R | 1 |
| Chu, Y | 1 |
| Glass, J | 1 |
| Nelson, B | 1 |
| Brown, SA | 1 |
| Clark, JI | 1 |
| Livesey, JC | 1 |
| Steele, JE | 1 |
| Paine, GD | 1 |
| Taylor, CW | 1 |
| Lopez, MH | 1 |
| Johnson, CS | 1 |
| Capizzi, RL | 1 |
| Lenoble, M | 1 |
| Fichtner, I | 1 |
| Lemm, M | 1 |
| Becker, M | 1 |
| Berthold, F | 1 |
| Nici, L | 1 |
| Santos-Moore, A | 1 |
| Kuhn, C | 1 |
| Calabresi, P | 1 |
| Tamurian, RM | 1 |
| Bohuslavizki, KH | 1 |
| Klutmann, S | 1 |
| Jenicke, L | 1 |
| Brenner, W | 1 |
| Feyerabend, B | 1 |
| Henze, E | 1 |
| Clausen, M | 1 |
| Lindegaard, JC | 1 |
| Grau, C | 1 |
| Shaker, JL | 1 |
| Fallon, MD | 1 |
| Goldfarb, S | 1 |
| Farber, J | 1 |
| Attie, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel[NCT04995328] | 23 participants (Actual) | Interventional | 2021-08-03 | Completed | |||
| A Phase I Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers[NCT02587442] | Phase 1 | 27 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amifostine anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
Has the outlook improved for amifostine as a clinical radioprotector?
Topics: Amifostine; Animals; Clinical Trials as Topic; Disease Models, Animal; Dogs; Dose-Response Relations | 2000 |
1 trial available for amifostine anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
31 other studies available for amifostine anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway.
Topics: Amifostine; Animals; Bleomycin; Disease Models, Animal; Mammals; Mice; Nasopharyngeal Neoplasms; Pho | 2023 |
Polycysteine as a new type of radio-protector ameliorated tissue injury through inhibiting ferroptosis in mice.
Topics: Amifostine; Animals; Cell Line; Disease Models, Animal; DNA; Ferroptosis; Glutathione; Hematopoietic | 2021 |
Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress.
Topics: Amifostine; Animals; Apoptosis; Cell Survival; Cells, Cultured; Disease Models, Animal; Mice; Mitoch | 2017 |
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv | 2019 |
Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Topics: Amifostine; Animals; Blood Pressure; Breast Neoplasms; Disease Models, Animal; DNA Damage; Dogs; Dru | 2019 |
The ameliorative effect of various antioxidants on Adriamycin-induced fetal renal abnormalities.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antioxidants; Deferoxamine; Disease Models, Animal | 2013 |
Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: a randomized controlled trial.
Topics: Abdominal Wall; Acetylcysteine; Amifostine; Animals; Disease Models, Animal; Endometriosis; Endometr | 2014 |
Amifostine protects vascularity and improves union in a model of irradiated mandibular fracture healing.
Topics: Amifostine; Animals; Disease Models, Animal; Fracture Healing; Humans; Mandible; Mandibular Fracture | 2013 |
Cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against methotrexate-induced hepatotoxicity in rats.
Topics: Acetylcysteine; Amifostine; Animals; Antioxidants; Ascorbic Acid; Biomarkers; Chemical and Drug Indu | 2014 |
The effect of amifostine on pathophysiological changes in vasogenic brain edema induced by an experimental cold injury model.
Topics: Amifostine; Animals; Brain Edema; Brain Injuries; Cold Temperature; Dexamethasone; Disease Models, A | 2015 |
CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice.
Topics: Acute Radiation Syndrome; Amifostine; Animals; Disease Models, Animal; Dose-Response Relationship, R | 2015 |
Prophylactic amifostine prevents a pathologic vascular response in a murine model of expander-based breast reconstruction.
Topics: Amifostine; Angiography; Animals; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationsh | 2016 |
The effect of amifostine on lung ischaemia-reperfusion injury in rats.
Topics: Amifostine; Animals; Disease Models, Animal; Inflammation Mediators; Ischemia; Lung; Male; NF-kappa | 2016 |
Radioprotection of osteoblasts by a fractionated dose regimen and amifostine.
Topics: Amifostine; Animals; Animals, Newborn; Cell Differentiation; Cell Proliferation; Cell Survival; Dise | 2009 |
Sequential histomorphometric analysis of the growth plate following irradiation with and without radioprotection.
Topics: Age Factors; Amifostine; Animals; Anthropometry; Chondrocytes; Disease Models, Animal; Dose-Response | 2003 |
Transiently increased bone density after irradiation and the radioprotectant drug amifostine in a rat model.
Topics: Amifostine; Animals; Bone Density; Disease Models, Animal; Hindlimb; Male; Osteoclasts; Radiation-Pr | 2003 |
Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Disease Models, Animal; Drug Deli | 2004 |
WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Topics: Amifostine; Animals; Auditory Threshold; Cisplatin; Cochlea; Cricetinae; Disease Models, Animal; Dos | 2004 |
Effects of amifostine on glycerol-pretreated rabbit kidneys.
Topics: Acetylcholine; Acute Kidney Injury; Amifostine; Animals; Antioxidants; Blood Pressure; Disease Model | 2005 |
Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone.
Topics: Amifostine; Animals; Anti-Ulcer Agents; Bone Development; Disease Models, Animal; Dose Fractionation | 2005 |
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.
Topics: Acetaldehyde; Acetyl Coenzyme A; Adenosine Triphosphate; Amifostine; Animals; Disease Models, Animal | 2008 |
Amifostine prior to lethal irradiation prevents allogeneic bone marrow engraftment in mice.
Topics: Amifostine; Animals; Bone Marrow Transplantation; Disease Models, Animal; Graft Rejection; Graft Sur | 2008 |
Phase separation inhibitors and lens transparency.
Topics: Amifostine; Animals; Cataract; Disease Models, Animal; Female; Galactose; Lens, Crystalline; Male; R | 1993 |
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combin | 1996 |
Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Topics: Amifostine; Animals; Antineoplastic Agents; Blood Platelets; Body Weight; Disease Models, Animal; Fe | 1997 |
Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant amifostine.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antioxidants; Bleomycin; Collagen; Cricetinae; Dis | 1998 |
Sparing radiation-induced damage to the physis by radioprotectant drugs: laboratory analysis in a rat model.
Topics: Amifostine; Animals; Bone Development; Disease Models, Animal; Femur; Growth Plate; Hindlimb; Pilot | 1999 |
Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model.
Topics: Amifostine; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Iodine Radioisotopes; Mal | 1999 |
WR-2721 reduces bone loss after hindlimb tenotomy in rats.
Topics: Amifostine; Animals; Bone Resorption; Calcium; Data Interpretation, Statistical; Disease Models, Ani | 1989 |